Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BOTOX dose-ranging placebo-controlled phase 3 trial in neurogenic detrusor overactivity
NL-OMON31043Phase 3Active, not recruiting
- Sponsor
- GCP-Service International
- Start
- Oct 2007
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of botulinum toxin type A in detrusor hyperreflexia (DH), urinary incontinence (UI) and overactive bladder (OAB) (3 arms), sponsored by GCP-Service International. Primary endpoint: Number of urinary incontinence episodes. Started Oct 2007; status: active, not recruiting.
02
Drugs
botulinum toxin type A
03
Conditions
detrusor hyperreflexia (DH)urinary incontinence (UI)overactive bladder (OAB)
Beyond the preview
Go deeper on NL-OMON31043.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON31043.